Cancers, Vol. 16, Pages 1383: Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis

Cancers, Vol. 16, Pages 1383: Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis Cancers doi: 10.3390/cancers16071383 Authors: Lynh Nguyen Aditi Saha Andrew Kuykendall Ling Zhang Hypereosinophilia (HE) presents with an elevated peripheral eosinophilic count of >1.5 × 109/L and is composed of a broad spectrum of secondary non-hematologic disorders and a minority of primary hematologic processes with heterogenous clinical presentations, ranging from mild symptoms to potentially lethal outcome secondary to end-organ damage. Following the introduction of advanced molecular diagnostics (genomic studies, RNA sequencing, and targeted gene mutation profile, etc.) in the last 1–2 decades, there have been deep insights into the etiology and molecular mechanisms involved in the development of HE. The classification of HE has been updated and refined following to the discovery of clinically novel markers and targets in the 2022 WHO classification and ICOG-EO 2021 Working Conference on Eosinophil Disorder and Syndromes. However, the diagnosis and management of HE is challenging given its heterogeneity and variable clinical outcome. It is critical to have a diagnostic algorithm for accurate subclassification of HE and hypereosinophilic syndrome (HES) (e.g., reactive, familial, idiopathic, myeloid/lymphoid neoplasm, organ restricted, or with unknown significance) and to follow established treatmen...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research